Abstract

Extemporaneous Compounding of Oral Acitretin Suspension for Pediatric Patient with Generalized Pustular Psoriasis

Author(s): Choo Winnie

Issue: Jan/Feb 2016 - Volume 20, Number 1

Page(s): 6-10

Download in electronic PDF format for $75
  • Extemporaneous Compounding of Oral Acitretin Suspension for Pediatric Patient with Generalized Pustular Psoriasis Page 1
  • Extemporaneous Compounding of Oral Acitretin Suspension for Pediatric Patient with Generalized Pustular Psoriasis Page 2
  • Extemporaneous Compounding of Oral Acitretin Suspension for Pediatric Patient with Generalized Pustular Psoriasis Page 3
  • Extemporaneous Compounding of Oral Acitretin Suspension for Pediatric Patient with Generalized Pustular Psoriasis Page 4
  • Extemporaneous Compounding of Oral Acitretin Suspension for Pediatric Patient with Generalized Pustular Psoriasis Page 5

Abstract

Generalized pustular psoriasis is rare in children, but it can occur and affect an extensive body surface area of a child. Treatment regimens can include medications that are not available in pediatric dosage form. Acitretin is considered one of the treatment options for acute generalized pustular psoriasis in children, but, in Singapore, it is only available as Neotigason capsules. Extemporaneous compounding of the powder content in the capsules was developed for formulating the oral acitretin suspension with a standardized formulation table and compounding process at National Skin Centre. An appropriate beyond-use date of the extemporaneous preparation was assigned after reviewing the photostability data of acitretin, compatibility of the active ingredient and excipients, and United States Pharmacopeia <795> guidelines. It is deemed appropriate to assign a beyond-use date of 14 days when the extemporaneous preparation is stored in amber glass bottles at 2°C to 8°C.

Related Keywords

  • generalized pustular psoriasis
  • children
  • infants
  • inflammatory skin disorder
  • immune-mediated skin disorder
  • Singapore
  • acitretin
  • oral suspension
  • case report
  • photostability
  • Neotigason
  • compatibility
  • beyond-use date

Related Categories

  • DERMATOLOGY
  • PEDIATRICS
  • STABILITIES, COMPATIBILITIES
  • CASE REPORTS
  • ALLERGY/IMMUNOLOGY/INFLAMMATION
  • DOSAGE FORMS/DRUG CARRIERS

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Jan/Feb 2016
Pg. 6-10
Extemporaneous Compounding of Oral Acitretin Suspension for Pediatric Patient with Generalized Pustular Psoriasis
Author(s): Choo Winnie
Sep/Oct 2009
Pg. 386-389
Skin Disorders in Horses; Case Report: Tripelennamine in the Treatment of Skin Disorders in Horses
Author(s): Williams LaVonn A, Fokken Dawn
Jan/Feb 2001
Pg. 6-8
Pediatric Compounding: Coloring Outside the Lines
Author(s): Preckshot John
May/Jun 2017
Pg. 205-211
Management of Psoriasis with a XemaTop Topical Compounded Formula: A Case Report
Author(s): Jones Nat, Carvalho Maria, Branvold-Herr Andrea
Jul/Aug 2019
Pg. 324-331
Extemporaneous Indomethacin Oral Suspension Prepared from Injectable Ampules for Therapy in Premature Infants and Pediatric Patients
Author(s): de Lafuente Yanina, García Mónica Cristina, Jiminez-Kairuz Alvaro
Nov/Dec 2003
Pg. 460-463
View Sample
Basics of Compounding for Dry-Skin Conditions
Author(s): Allen Loyd V Jr
Jan/Feb 2004
Pg. 46-48
Basics of Compounding for Disorders of the External Ear
Author(s): Allen Loyd V Jr
Jan/Feb 2001
Pg. 9-12
Stability Issues for Compounding Extemporaneously Prepared Oral Formulations for Pediatric Patients
Author(s): Schotik Debora
May/Jun 2016
Pg. 247-249
Extended Stability of Morphine and Sildenafil for Oral Use in Infants and Young Children
Author(s): Nahata Milap C
May/Jun 2016
Pg. 257-261
Development of Extemporaneously Compounded Aripiprazole Oral Suspensions for Use in Children
Author(s): Pramann Lance A, Davidow Lawrence W, van Haandel Leon, Funk Ryan S
Sep/Oct 2015
Pg. 357-365
Novel Approaches to Topical Psoriasis Therapy
Author(s): Koyama Gregory, Liu Jenny, Scaffidi Alyse, Khazraee Maryam, Epstein Benjamin
May/Jun 2011
Pg. 204-213
Treatment Options for Psoriasis
Author(s): Williams LaVonn A, Humphreys Erica
Nov/Dec 2021
Pg. 502
Levetiracetam 50 mg/mL in Ora-Sweet and Ora-Plus Suspension
Author(s): Allen Loyd V Jr
Sep/Oct 2003
Pg. 389-393
Formulation and Accelerated Stability Studies for an Extemporaneous Suspension of Amiodarone Hydrochloride
Author(s): Alexander Kenneth S, Thyangarajapuram N
Jul/Aug 2020
Pg. 327-336
Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4
Author(s): Espana B, Joseph-Tornabène F, Jaquet Cécile, Perrot S, Prouillac C
Mar/Apr 1997
Pg. 84-86
Compounding for the Pediatric Patient
Author(s): Allen Loyd V Jr
Jul/Aug 2020
Pg. 337-345
Evaluation of the Efficacy and Stability of Compounded Pentoxifylline-containing XemaTop for Psoriasis
Author(s): Song Guiyun, Ip Kendice, Shan Ashley, Banov Daniel, Bassani August S
Jul/Aug 2018
Pg. 270-278
Compounded Low-dose Naltrexone for the Treatment of Guttate Psoriasis: A Case Report
Author(s): Muller George, Grieshaber Robert, Talley J Floyd, Riepl Mike, Fellows Don
Jan/Feb 2004
Pg. 10-14
Women's Oral Health: Is There a Hormonal Link?
Author(s): Preckshot John
Jul/Aug 2011
Pg. 340
Methylprednisolone 4-mg/mL Oral Suspension
Author(s): Allen Loyd V Jr